       Document 0637
 DOCN  M9610637
 TI    Immunity and immunopathology to respiratory syncytial virus. The mouse
       model.
 DT    9601
 AU    Openshaw PJ; St. Mary's Hospital Medical School, Imperial College of
       Science,; Technology and Medicine, London, United Kingdom.
 SO    Am J Respir Crit Care Med. 1995 Oct;152(4 Pt 2):S59-62. Unique
       Identifier : AIDSLINE MED/96023237
 AB    Infection with respiratory syncytial virus (RSV) is a major unsolved
       challenge for vaccine development. RSV is worldwide in distribution and
       infects almost all children during the first 2 yr of life. The mouse
       model of RSV lung disease has been very successful in reproducing many
       aspects of the human disease. In particular, the role of antiviral T
       cells in both eliminating virus and causing enhanced disease has been
       shown dramatically. This immunopathologic paradox is now more clearly
       understood than for any other common human infection, largely due to
       insights gained from the mouse model. This review focuses on the unique
       ability of different RSV proteins to prime for specific functional
       subsets in the mouse, and the association between sensitization to the
       major surface glycoprotein G, the induction of T helper 2 cells, and the
       subsequent appearance of lung eosinophilia during RSV infection.
 DE    Animal  Bronchoalveolar Lavage Fluid/IMMUNOLOGY/VIROLOGY  Disease
       Models, Animal  Eosinophils/IMMUNOLOGY  Human  Immunization  Mice  Mice,
       Inbred BALB C  Respiratory Syncytial Virus
       Infections/*IMMUNOLOGY/PATHOLOGY/  PREVENTION & CONTROL  Respiratory
       Syncytial Viruses/IMMUNOLOGY  Support, Non-U.S. Gov't  T-Lymphocytes,
       Cytotoxic/IMMUNOLOGY  Th2 Cells/IMMUNOLOGY  Viral Proteins/IMMUNOLOGY
       JOURNAL ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

